DiFrancesco Dario
Department of Biosciences, University of Milano, IBF-CNR University of Milano Unit, Milan, Italy.
Front Physiol. 2020 Jan 22;10:1599. doi: 10.3389/fphys.2019.01599. eCollection 2019.
Cardiac pacemaking is a most fundamental cardiac function, thoroughly investigated for decades with a multiscale approach at organ, tissue, cell and molecular levels, to clarify the basic mechanisms underlying generation and control of cardiac rhythm. Understanding the processes involved in pacemaker activity is of paramount importance for a basic physiological knowledge, but also as a way to reveal details of pathological dysfunctions useful in the perspective of a therapeutic approach. Among the mechanisms involved in pacemaking, the "funny" (I) current has properties most specifically fitting the requirements for generation and control of repetitive activity, and has consequently received the most attention in studies of the pacemaker function. Present knowledge of the basic mechanisms of pacemaking and the properties of funny channels has led to important developments of clinical relevance. These include: (1) the successful development of heart rate-reducing agents, such as ivabradine, able to control cardiac rhythm and useful in the treatment of diseases such as coronary artery disease, heart failure and tachyarrhythmias; (2) the understanding of the genetic basis of disorders of cardiac rhythm caused by HCN channelopathies; (3) the design of strategies to implement biological pacemakers based on transfer of HCN channels or of stem cell-derived pacemaker cells expressing I, with the ultimate goal to replace electronic devices. In this review, I will give a brief historical account of the discovery of the funny current and the development of the concept of I-based pacemaking, in the context of a wider, more complex model of cardiac rhythmic function.
心脏起搏是一项最基本的心脏功能,数十年来一直采用多尺度方法在器官、组织、细胞和分子水平上进行深入研究,以阐明心脏节律产生和控制的基本机制。了解起搏活动所涉及的过程对于掌握基本生理知识至关重要,同时也是揭示病理功能障碍细节的一种方式,这对于治疗方法的制定具有重要意义。在起搏所涉及的机制中,“起搏电流”(I)具有最符合重复活动产生和控制要求的特性,因此在起搏器功能研究中受到了最多关注。目前对起搏基本机制和起搏通道特性的认识已带来了具有临床相关性的重要进展。这些进展包括:(1)成功开发出降低心率的药物,如伊伐布雷定,它能够控制心律,对治疗冠状动脉疾病、心力衰竭和快速性心律失常等疾病有用;(2)了解由超极化激活的环核苷酸门控通道(HCN)病引起的心律失常的遗传基础;(3)设计基于HCN通道或表达I的干细胞衍生起搏细胞移植来实现生物起搏器的策略,最终目标是取代电子设备。在这篇综述中,我将在更广泛、更复杂的心脏节律功能模型背景下,简要介绍起搏电流的发现历程以及基于I的起搏概念的发展。